Search by Abstract Number Results

Abstract Number: L13 • ACR Convergence 2024
Anifrolumab Long-Term Treatment Is More Effective Against Organ Damage Than Standard of Care Alone: Results from an External Control Arm Study on Organ Damage in Phase 3 Clinical Trials and the University of Toronto Lupus Clinic Cohort
Zahi Touma¹, Ian Bruce², Richard A. Furie³, Eric Morand⁴, Raj Tummala⁵, Shelly Chandran⁶, Gabriel Abreu⁷, Jacob Knagenhjelm⁷, Kellyn Arnold⁸, Hopin Lee⁸, Eleanor Ralphs⁸, Danuta Kielar⁹, Aleksander Bedenkov⁹ and Miina Waratani⁹, ¹Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ²Queen's University Belfast, Belfast, United Kingdom, ³Northwell Health, Manhasset, NY, ⁴Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁶Astrazeneca, Mississauga, ON, Canada, ⁷BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁸IQVIA, London, United Kingdom, ⁹Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: In SLE, persistent disease activity, disease flares and long-term glucocorticoid (GC) use all contribute to organ damage accrual. The effects of novel therapies on…
Abstract Number: L13 • ACR Convergence 2023
An Open-label, Multicenter, Phase 1/2 Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323, a Rapid Manufacturing CAR-T Cell Therapy Targeting CD19 on B Cells, for Severe Refractory Systemic Lupus Erythematosus: Preliminary Results
Josefina Cortés Hernández¹, Pere Barba², Mònica Linares Alberich³, Ozana Fischer⁴, Beata Kovacs⁴, Thomas Calzascia⁴, David Pearson⁴, Ana-Laura Jordán Garrote⁵, Tiina Kirsilä⁴, Richard Siegel⁴, Tamas Shisha⁴, Giulio Cavalli⁴ and Peter Gergely⁴, ¹Vall d'Hebron Institute of Research (VHIR) and Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Catalonia, Spain, ²Vall d'Hebron Institute of Oncology and Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Catalonia, Spain, ³Banc de Sang i Teixits, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain, ⁴Novartis Biomedical Research, Basel, Basel-Stadt, Switzerland, ⁵Novartis Farmacéutica, Barcelona, Catalonia, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by pathogenic autoreactive B cells producing autoantibodies against multiple self-antigens. Recently, a series of clinical cases suggested that…
Abstract Number: L13 • ACR Convergence 2022
Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block
Stephanie Benjamin¹, Lisa Vi², Diptendu Chatterjee¹, Edgar Jaeggi¹, Marie Wahren-Herlenius³, Amelia Ruffatti⁴, Linda Hiraki⁵, Michelle Lohbihler², Lusia Sepiashvili¹, Carl Laskin⁶, Meena Fatah¹, Daniela Dominguez⁵, Lawrence Ng⁵, Anthony Gramolini², Vincent Christoffels⁷, Stephanie Protze² and Robert Hamilton⁸, ¹Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ⁴Universitå di Padova, Padova, Italy, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶Mt. Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁷Amsterdam UMC, Amsterdam, Zuid-Holland, Netherlands, ⁸Hospital for Sick Children, Markham, ON, Canada
Background/Purpose: Autoimmune congenital heart block (CHB+) affects the fetus of mothers with anti-Ro antibodies. Anti-Ro (Ro+) antibodies (Abs) are usually present in maternal sera when…
Abstract Number: L13 • ACR Convergence 2021
Efficacy and Safety of Subcutaneous Belimumab (BEL) and Rituximab (RTX) Sequential Therapy in Patients with Systemic Lupus Erythematosus: The Phase 3, Randomized, Placebo-Controlled BLISS-BELIEVE Study
Cynthia Aranow¹, Cornelia Allaart², Zahir Amoura³, Ian N Bruce⁴, Patricia Cagnoli⁵, Richard Furie¹, Paul Peter Tak⁶, Murray Urowitz⁷, Ronald van Vollenhoven⁸, Kenneth L Clark⁶, Mark Daniels⁹, Norma Lynn Fox¹⁰, Yun Irene Gregan¹⁰, James Groark¹¹, Robert B Henderson⁹, Mary Oldham⁹, Don Shanahan⁹, Andre van Maurik⁹, David A Roth¹⁰ and YK Onno Teng², ¹Feinstein Institutes for Medical Research, Northwell Health, Great Neck, NY, ²Leiden University Medical Center, Leiden, Netherlands, ³Centre National de reference pour le Lupus, Service de Medecine Interne 2, Institut E3M, Hopital Pitié-Salpétrière, Paris, France, ⁴NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Trust and Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵University of Michigan Medical Center, Ann Arbor, MI, ⁶GlaxoSmithKline (At the time of the author's contribution to this study), Stevenage, United Kingdom, ⁷Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁸Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁹GlaxoSmithKline, Stevenage, United Kingdom, ¹⁰GlaxoSmithKline, Collegeville, PA, ¹¹GlaxoSmithKline (At the time of the author's contribution to this study), Collegeville, PA
Background/Purpose: Disease control remains an unmet need in SLE. The rationale for sequential BEL and RTX therapy in SLE was previously published.1 This study evaluated…
Abstract Number: L13 • 2019 ACR/ARP Annual Meeting
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
Philip J. Mease¹, Proton Rahman ², Alice B. Gottlieb ³, Elizabeth Hsia ⁴, Alexa Kollmeier ⁵, Xie Xu ⁶, Ramanand Subramanian ⁵, Prasheen Agarwal ⁵, Shihong Sheng ⁵, Bei Zhou ⁵, Désirée van der Heijde ⁷ and Iain McInnes ⁸, ¹Swedish Medical Center and University of Washington, Seattle, Washington, ²Memorial University of Newfoundland, Newfoundland, Canada, ³Icahn School of Medicine at Mt Sinai, NY, NY, New York, New York, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, Pennsylvania, ⁵Janssen Research & Development, LLC, Spring House, Pennsylvania, ⁶Janssen Research & Development, LLC, Spring House, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved for psoriasis (PsO). We assessed GUS efficacy and safety in DISCOVER-1 (ACR2019 Abstract ID697955) and DISCOVER-2,…
Abstract Number: L13 • 2018 ACR/ARHP Annual Meeting
Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial
Xenofon Baraliakos¹, Jürgen Braun², Atul A. Deodhar³, Denis Poddubnyy⁴, Alan J. Kivitz⁵, Hasan Tahir⁶, Filip van Den Bosch⁷, Evie Maria Delicha⁸, Zsolt Talloczy⁹ and Anke Fierlinger⁹, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, and Ruhr University Bochum, Herne, Germany, Herne, Germany, ³Oregon Health & Science University, Portland, Portland, OR, ⁴Rheumatology, Campus Benjamin Franklin Charité – Universitätsmedizin, Germany and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁵Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁶Whipps Cross University Hospital, Barts Health NHS Trust, London, United Kingdom, ⁷Rheumatology, Universitair Ziekenhuis, Ghent, Belgium, Gent, Belgium, ⁸Novartis Pharma AG, Basel, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States, East Hanover, NJ
Background/Purpose: Clinical evaluation of efficacy and safety for long-term treatment for ankylosing spondylitis (AS) is important for treatment decision-making. Secukinumab (SEC), a fully human mAb…
Abstract Number: L13 • 2014 ACR/ARHP Annual Meeting
Monthly Ibandronate Reduces Bone Loss in Osteopenic Women with Rheumatoid Arthritis Receiving Long-Term Glucocorticoids: A 48-Week Double-Blinded Randomized Placebo-Controlled Investigator-Initiated Trial
Kichul Shin¹, Sung-Hwan Park², Won Park³, Han Joo Baek⁴, Yun Jong Lee⁵, Seong-Wook Kang⁶, Jung-Yoon Choe⁷, Wan-Hee Yoo⁸, Yong-Beom Park⁹, Jung-Soo Song¹⁰, Bin Yoo¹¹, Dae-Hyun Yoo¹² and Yeong Wook Song¹³, ¹Rheumatology, SMG-SNU Boramae Medical Center, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Medicine/Rheumatology, Inha University Hospital, Incheon, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁶Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, ⁷Division of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁸Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ¹⁰Rheumatology, Chung-Ang Univ Hospital, Seoul, South Korea, ¹¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ¹²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹³Department of Molecular Medicine and Biopharmaceutical Sciences, BK 21 plus Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, South Korea
Background/Purpose: Long-term use of glucocorticoids (GC) is problematic for patients with increased risk for vertebral fractures, especially those with rheumatoid arthritis (RA). Thus, prevention of…
Abstract Number: L13 • 2013 ACR/ARHP Annual Meeting
Serum 14-3-3η Marks RA Development in Arthralgia and Radiographic Progression in Early RA Patients
D. van Schaardenburg¹, Marian van Beers-Tas², Karin Britsemmer², Mairead Murphy³, Walter P. Maksymowych⁴, Maarten Boers⁵ and Anthony Marotta⁶, ¹Jan van Breemen Research Institute, Amsterdam, Netherlands, ²Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁶Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: The focus of RA management is increasingly towards early detection and treatment. While newly-diagnosed patients will benefit from treatment decisions based on more robust…
Abstract Number: L13 • 2012 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial
Arthur Kavanaugh¹, Philip J. Mease², Juan J. Gomez-Reino³, Adebajo Adewale⁴, Jürgen Wollenhaupt⁵, ChiaChi Hu⁶ and Randall Stevens⁶, ¹UCSD School of Medicine, La Jolla, CA, ²Rheumatology Research, Swedish Medical Center, Seattle, WA, ³Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ⁴University of Sheffield, Sheffield, United Kingdom, ⁵Schön Klinik Hamburg Eilbek, Hamburg, Germany, ⁶Celgene Corporation, Warren, NJ
Background/Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate a network of pro- and anti-inflammatory mediators, including those implicated in the etiopathogenesis of…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].